Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Fosaprepitant (IVEMEND®) is recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy. |
|||
|
|||
Medicine details |
|||
| Medicine name | fosaprepitant (IVEMEND®) | ||
| Formulation | 150 mg powder for solution for infusion | ||
| Reference number | 3789 | ||
| Indication | Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as a part of a combination therapy. |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Gastro-intestinal system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2018 | ||
| NMG meeting date | 10/10/2018 | ||
| AWMSG meeting date | 14/11/2018 | ||
| Date of issue | 03/12/2018 | ||
| Date of last review | April 2022 | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||